VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q4 2022. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,570,537 | +2.0% | 70,038 | -0.0% | 0.01% | +10.0% |
| Q2 2023 | $3,498,896 | +75.4% | 70,062 | +31.6% | 0.01% | +66.7% |
| Q1 2023 | $1,994,723 | -20.1% | 53,221 | +2.2% | 0.01% | -25.0% |
| Q4 2022 | $2,497,524 | -56.2% | 52,086 | -78.1% | 0.01% | -55.6% |
| Q3 2022 | $5,698,000 | +44.2% | 237,433 | +30.8% | 0.02% | +80.0% |
| Q2 2022 | $3,951,000 | -21.1% | 181,589 | -12.4% | 0.01% | 0.0% |
| Q1 2022 | $5,005,000 | +1.5% | 207,240 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $4,930,000 | +15.5% | 207,240 | +23.2% | 0.01% | +11.1% |
| Q3 2021 | $4,269,000 | +47.4% | 168,280 | +30.8% | 0.01% | +50.0% |
| Q2 2021 | $2,896,000 | +41.6% | 128,675 | +24.3% | 0.01% | +50.0% |
| Q1 2021 | $2,045,000 | +19.2% | 103,520 | +60.3% | 0.00% | 0.0% |
| Q4 2020 | $1,715,000 | +20.6% | 64,560 | +124.2% | 0.00% | 0.0% |
| Q3 2020 | $1,422,000 | – | 28,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |